William Hope

List of Publications by Citations

182 papers	12,601 citations	50 h-index	109 g-index
195 ext. papers	14,573 ext. citations	7.2 avg, IF	6.25 L-index

#	Paper	IF	Citations
182	Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. *Clinical Infectious Diseases*, **2008**, 46, 1813-21	11.6	3744
181	Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions. *Lancet Infectious Diseases, The*, **2014**, 14, 498-509	25.5	534
180	Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial. *Lancet, The*, **2016**, 387, 760-9	40	501
179	Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology. *Journal of Antimicrobial Chemotherapy*, **2014**, 69, 1162-76	5.1	404
178	Laboratory diagnosis of invasive aspergillosis. *Lancet Infectious Diseases, The*, **2005**, 5, 609-22	25.5	378
177	EUCAST technical note on the EUCAST definitive document EDef 7.2: method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for yeasts EDef 7.2 (EUCAST-AFST). *Clinical Microbiology and Infection*, **2012**, 18, E246-7	9.5	277
176	Fourth European Conference on Infections in Leukaemia (ECIL-4): guidelines for diagnosis, prevention, and treatment of invasive fungal diseases in paediatric patients with cancer or allogeneic haemopoietic stem-cell transplantation. *Lancet Oncology, The*, **2014**, 15, e327-40	21.7	274
175	Tissue penetration of antifungal agents. *Clinical Microbiology Reviews*, **2014**, 27, 68-88	34	234
174	Therapy for fungal diseases: opportunities and priorities. *Trends in Microbiology*, **2010**, 18, 195-204	12.4	225
173	Liposomal Amphotericin B (AmBisome(®)): A Review of the Pharmacokinetics, Pharmacodynamics, Clinical Experience and Future Directions. *Drugs*, **2016**, 76, 485-500	12.1	208
172	ESCMID* guideline for the diagnosis and management of Candida diseases 2012: prevention and management of invasive infections in neonates and children caused by Candida spp. *Clinical Microbiology and Infection*, **2012**, 18 Suppl 7, 38-52	9.5	206
171	Observational study of the clinical efficacy of voriconazole and its relationship to plasma concentrations in patients. *Antimicrobial Agents and Chemotherapy*, **2011**, 55, 4782-8	5.9	168
170	F901318 represents a novel class of antifungal drug that inhibits dihydroorotate dehydrogenase. *Proceedings of the National Academy of Sciences of the United States of America*, **2016**, 113, 12809-12814	11.5	121
169	Pharmacokinetics of an elevated dosage of micafungin in premature neonates. *Pediatric Infectious Disease Journal*, **2009**, 28, 412-5	3.4	112
168	Molecular mechanisms of primary resistance to flucytosine in Candida albicans. *Antimicrobial Agents and Chemotherapy*, **2004**, 48, 4377-86	5.9	109
167	Therapeutic drug monitoring for triazoles. *Current Opinion in Infectious Diseases*, **2008**, 21, 580-6	5.4	106
166	Efficacy and safety of posaconazole for chronic pulmonary aspergillosis. *Clinical Infectious Diseases*, **2010**, 51, 1383-91	11.6	105

165	Increase in prevalence of nosocomial non-Candida albicans candidaemia and the association of Candida krusei with fluconazole use. *Journal of Hospital Infection*, **2002**, 50, 56-65	6.9	104
164	EUCAST technical note on Aspergillus and amphotericin B, itraconazole, and posaconazole. *Clinical Microbiology and Infection*, **2012**, 18, E248-50	9.5	101
163	Breakpoints for antifungal agents: an update from EUCAST focussing on echinocandins against Candida spp. and triazoles against Aspergillus spp. *Drug Resistance Updates*, **2013**, 16, 81-95	23.2	98
162	Differential in vivo activities of anidulafungin, caspofungin, and micafungin against Candida glabrata isolates with and without FKS resistance mutations. *Antimicrobial Agents and Chemotherapy*, **2012**, 56, 2435-42	5.9	98
161	Population pharmacokinetics of micafungin in neonates and young infants. *Antimicrobial Agents and Chemotherapy*, **2010**, 54, 2633-7	5.9	96
160	Applying pharmacokinetic/pharmacodynamic principles in critically ill patients: optimizing efficacy and reducing resistance development. *Seminars in Respiratory and Critical Care Medicine*, **2015**, 36, 136-53	3.9	93
159	Toxicodynamics of itraconazole: implications for therapeutic drug monitoring. *Clinical Infectious Diseases*, **2009**, 49, 928-30	11.6	91
158	Changes in the incidence of candidiasis in neonatal intensive care units. *Pediatrics*, **2014**, 133, 236-42	7.4	90
157	Safety and pharmacokinetics of repeat-dose micafungin in young infants. *Clinical Pharmacology and Therapeutics*, **2010**, 87, 93-9	6.1	90
156	Therapeutic drug monitoring of the β-lactam antibiotics: what is the evidence and which patients should we be using it for?. *Journal of Antimicrobial Chemotherapy*, **2015**, 70, 3178-83	5.1	88
155	Pharmacokinetics and pharmacodynamics of posaconazole for invasive pulmonary aspergillosis: clinical implications for antifungal therapy. *Journal of Infectious Diseases*, **2011**, 203, 1324-32	7	87
154	Population pharmacokinetics of micafungin in pediatric patients and implications for antifungal dosing. *Antimicrobial Agents and Chemotherapy*, **2007**, 51, 3714-9	5.9	85
153	Fluconazole loading dose pharmacokinetics and safety in infants. *Pediatric Infectious Disease Journal*, **2011**, 30, 375-8	3.4	82
152	Combination therapy in treatment of experimental pulmonary aspergillosis: in vitro and in vivo correlations of the concentration- and dose- dependent interactions between anidulafungin and voriconazole by Bliss independence drug interaction analysis. *Antimicrobial Agents and Chemotherapy*, **2009**, 53, 2382-94	5.9	81
151	Population pharmacokinetics of voriconazole in adults. *Antimicrobial Agents and Chemotherapy*, **2012**, 56, 526-31	5.9	76
150	Therapeutic drug monitoring for invasive mould infections and disease: pharmacokinetic and pharmacodynamic considerations. *Journal of Antimicrobial Chemotherapy*, **2017**, 72, i12-i18	5.1	74
149	Pharmacodynamics of fosfomycin: insights into clinical use for antimicrobial resistance. *Antimicrobial Agents and Chemotherapy*, **2015**, 59, 5602-10	5.9	72
148	Pharmacokinetics and pharmacodynamics of a novel triazole, isavuconazole: mathematical modeling, importance of tissue concentrations, and impact of immune status on antifungal effect. *Antimicrobial Agents and Chemotherapy*, **2009**, 53, 3453-61	5.9	72

147	Generating Robust and Informative Nonclinical and Bacterial Infection Model Efficacy Data To Support Translation to Humans. *Antimicrobial Agents and Chemotherapy*, **2019**, 63,	5.9	69
146	Itraconazole: an update on pharmacology and clinical use for treatment of invasive and allergic fungal infections. *Expert Opinion on Drug Metabolism and Toxicology*, **2013**, 9, 911-26	5.5	68
145	Characterization and comparison of galactomannan enzyme immunoassay and quantitative real-time PCR assay for detection of Aspergillus fumigatus in bronchoalveolar lavage fluid from experimental invasive pulmonary aspergillosis. *Journal of Clinical Microbiology*, **2006**, 44, 2475-80	9.7	66
144	EUCAST technical note on voriconazole and Aspergillus spp. *Clinical Microbiology and Infection*, **2013**, 19, E278-80	9.5	63
143	Population pharmacokinetics of extended-infusion piperacillin-tazobactam in hospitalized patients with nosocomial infections. *Antimicrobial Agents and Chemotherapy*, **2012**, 56, 4087-94	5.9	61
142	The initial 96 hours of invasive pulmonary aspergillosis: histopathology, comparative kinetics of galactomannan and (1->3) Ed-glucan and consequences of delayed antifungal therapy. *Antimicrobial Agents and Chemotherapy*, **2010**, 54, 4879-86	5.9	59
141	In vitro susceptibility of Aspergillus fumigatus to isavuconazole: correlation with itraconazole, voriconazole, and posaconazole. *Antimicrobial Agents and Chemotherapy*, **2013**, 57, 5778-80	5.9	58
140	Dynamic ploidy changes drive fluconazole resistance in human cryptococcal meningitis. *Journal of Clinical Investigation*, **2019**, 129, 999-1014	15.9	57
139	Plasma and peritoneal fluid population pharmacokinetics of micafungin in post-surgical patients with severe peritonitis. *Journal of Antimicrobial Chemotherapy*, **2015**, 70, 2854-61	5.1	52
138	Individualization of piperacillin dosing for critically ill patients: dosing software to optimize antimicrobial therapy. *Antimicrobial Agents and Chemotherapy*, **2014**, 58, 4094-102	5.9	52
137	Exposure-Response Relationships for Isavuconazole in Patients with Invasive Aspergillosis and Other Filamentous Fungi. *Antimicrobial Agents and Chemotherapy*, **2017**, 61,	5.9	52
136	Safety and pharmacokinetics of multiple-dose anidulafungin in infants and neonates. *Clinical Pharmacology and Therapeutics*, **2011**, 89, 702-7	6.1	52
135	Impact of Bolus dosing versus continuous infusion of Piperacillin and Tazobactam on the development of antimicrobial resistance in Pseudomonas aeruginosa. *Antimicrobial Agents and Chemotherapy*, **2013**, 57, 5811-9	5.9	51
134	EUCAST technical note on anidulafungin. *Clinical Microbiology and Infection*, **2011**, 17, E18-20	9.5	50
133	Galactomannan antigen detection in the diagnosis of invasive aspergillosis. *Expert Review of Molecular Diagnostics*, **2007**, 7, 21-32	3.8	50
132	Evaluation of the pharmacokinetics and clinical utility of isavuconazole for treatment of invasive fungal infections. *Expert Opinion on Drug Metabolism and Toxicology*, **2012**, 8, 759-65	5.5	49
131	Achieving target voriconazole concentrations more accurately in children and adolescents. *Antimicrobial Agents and Chemotherapy*, **2015**, 59, 3090-7	5.9	48
130	Short-course High-dose Liposomal Amphotericin B for Human Immunodeficiency Virus-associated Cryptococcal Meningitis: A Phase 2 Randomized Controlled Trial. *Clinical Infectious Diseases*, **2019**, 68, 393-401	11.6	47

129	EUCAST technical note on Amphotericin B. *Clinical Microbiology and Infection*, **2011**, 17, E27-9	9.5	47
128	Disseminated Candidiasis caused by Candida albicans with amino acid substitutions in Fks1 at position Ser645 cannot be successfully treated with micafungin. *Antimicrobial Agents and Chemotherapy*, **2011**, 55, 3075-83	5.9	47
127	Pharmacokinetics and pharmacodynamics of fluconazole for cryptococcal meningoencephalitis: implications for antifungal therapy and in vitro susceptibility breakpoints. *Antimicrobial Agents and Chemotherapy*, **2013**, 57, 2793-800	5.9	46
126	Cerebrospinal fluid and plasma (1-->3)-beta-D-glucan as surrogate markers for detection and monitoring of therapeutic response in experimental hematogenous Candida meningoencephalitis. *Antimicrobial Agents and Chemotherapy*, **2008**, 52, 4121-9	5.9	46
125	How severe is antibiotic pharmacokinetic variability in critically ill patients and what can be done about it?. *Diagnostic Microbiology and Infectious Disease*, **2014**, 79, 441-7	2.9	45
124	Metallo-β-Lactamases: Structure, Function, Epidemiology, Treatment Options, and the Development Pipeline. *Antimicrobial Agents and Chemotherapy*, **2020**, 64,	5.9	44
123	Plasma and target-site subcutaneous tissue population pharmacokinetics and dosing simulations of cefazolin in post-trauma critically ill patients. *Journal of Antimicrobial Chemotherapy*, **2015**, 70, 1495-502	5.1	43
122	Pharmacokinetics and pharmacodynamics of amphotericin B deoxycholate, liposomal amphotericin B, and amphotericin B lipid complex in an in vitro model of invasive pulmonary aspergillosis. *Antimicrobial Agents and Chemotherapy*, **2010**, 54, 3432-41	5.9	43
121	Suppression of Emergence of Resistance in Pathogenic Bacteria: Keeping Our Powder Dry, Part 1. *Antimicrobial Agents and Chemotherapy*, **2015**, 60, 1183-93	5.9	42
120	Isavuconazole Population Pharmacokinetic Analysis Using Nonparametric Estimation in Patients with Invasive Fungal Disease (Results from the VITAL Study). *Antimicrobial Agents and Chemotherapy*, **2016**, 60, 4568-76	5.9	41
119	Considerations for effect site pharmacokinetics to estimate drug exposure: concentrations of antibiotics in the lung. *Current Opinion in Pharmacology*, **2017**, 36, 114-123	5.1	39
118	Tissue Distribution and Elimination of Isavuconazole following Single and Repeat Oral-Dose Administration of Isavuconazonium Sulfate to Rats. *Antimicrobial Agents and Chemotherapy*, **2017**, 61,	5.9	37
117	Pharmacodynamics of echinocandins against Candida glabrata: requirement for dosage escalation to achieve maximal antifungal activity in neutropenic hosts. *Antimicrobial Agents and Chemotherapy* , **2011**, 55, 4880-7	5.9	37
116	Antifungal pharmacokinetics and pharmacodynamics: bridging from the bench to bedside. *Clinical Microbiology and Infection*, **2009**, 15, 602-12	9.5	36
115	Pharmacodynamics of the Orotomides against : New Opportunities for Treatment of Multidrug-Resistant Fungal Disease. *MBio*, **2017**, 8,	7.8	36
114	Pharmacodynamics of Isavuconazole for Invasive Mold Disease: Role of Galactomannan for Real-Time Monitoring of Therapeutic Response. *Clinical Infectious Diseases*, **2017**, 64, 1557-1563	11.6	35
113	Effect of neutropenia and treatment delay on the response to antifungal agents in experimental disseminated candidiasis. *Antimicrobial Agents and Chemotherapy*, **2007**, 51, 285-95	5.9	34
112	EUCAST technical note on Candida and micafungin, anidulafungin and fluconazole. *Mycoses*, **2014**, 57, 377-9	5.2	33

111	An invertebrate model to evaluate virulence in Aspergillus fumigatus: the role of azole resistance. *Medical Mycology*, **2014**, 52, 311-9	3.9	33
110	Software for dosage individualization of voriconazole for immunocompromised patients. *Antimicrobial Agents and Chemotherapy*, **2013**, 57, 1888-94	5.9	33
109	Derivation of an in vivo drug exposure breakpoint for flucytosine against Candida albicans and Impact of the MIC, growth rate, and resistance genotype on the antifungal effect. *Antimicrobial Agents and Chemotherapy*, **2006**, 50, 3680-8	5.9	33
108	Suppression of Emergence of Resistance in Pathogenic Bacteria: Keeping Our Powder Dry, Part 2. *Antimicrobial Agents and Chemotherapy*, **2015**, 60, 1194-201	5.9	32
107	Optimizing management of invasive mould diseases. *Journal of Antimicrobial Chemotherapy*, **2011**, 66 Suppl 1, i45-53	5.1	32
106	Pharmacokinetics and Concentration-Dependent Efficacy of Isavuconazole for Treatment of Experimental Invasive Pulmonary Aspergillosis. *Antimicrobial Agents and Chemotherapy*, **2016**, 60, 2718-26	5.9	31
105	Pulmonary penetration of piperacillin and tazobactam in critically ill patients. *Clinical Pharmacology and Therapeutics*, **2014**, 96, 438-48	6.1	31
104	Anidulafungin for neonatal hematogenous Candida meningoencephalitis: identification of candidate regimens for humans using a translational pharmacological approach. *Antimicrobial Agents and Chemotherapy*, **2012**, 56, 708-14	5.9	31
103	Cerebrospinal fluid penetration of meropenem in neurocritical care patients with proven or suspected ventriculitis: a prospective observational study. *Critical Care*, **2016**, 20, 343	10.8	29
102	Population Pharmacokinetics of Liposomal Amphotericin B in Immunocompromised Children. *Antimicrobial Agents and Chemotherapy*, **2016**, 60, 7340-7346	5.9	28
101	Posaconazole: the case for therapeutic drug monitoring. *Therapeutic Drug Monitoring*, **2012**, 34, 72-6	3.2	27
100	Pharmacodynamics of teicoplanin against MRSA. *Journal of Antimicrobial Chemotherapy*, **2017**, 72, 3382-3389	5.1	26
99	Impact of unresolved neutropenia in patients with neutropenia and invasive aspergillosis: a post hoc analysis of the SECURE trial. *Journal of Antimicrobial Chemotherapy*, **2018**, 73, 757-763	5.1	26
98	Repurposing and Reformulation of the Antiparasitic Agent Flubendazole for Treatment of Cryptococcal Meningoencephalitis, a Neglected Fungal Disease. *Antimicrobial Agents and Chemotherapy*, **2018**, 62,	5.9	26
97	Antifungal agents and therapy for infants and children with invasive fungal infections: a pharmacological perspective. *British Journal of Clinical Pharmacology*, **2013**, 75, 1381-95	3.8	26
96	AMBIsome Therapy Induction OptimisatioN (AMBITION): High Dose AmBisome for Cryptococcal Meningitis Induction Therapy in sub-Saharan Africa: Study Protocol for a Phase 3 Randomised Controlled Non-Inferiority Trial. *Trials*, **2018**, 19, 649	2.8	26
95	Population pharmacokinetics of micafungin and its metabolites M1 and M5 in children and adolescents. *Antimicrobial Agents and Chemotherapy*, **2015**, 59, 905-13	5.9	25
94	Pharmacodynamics of vancomycin for CoNS infection: experimental basis for optimal use of vancomycin in neonates. *Journal of Antimicrobial Chemotherapy*, **2016**, 71, 992-1002	5.1	25

93	Pharmacodynamics of Voriconazole in Children: Further Steps along the Path to True Individualized Therapy. *Antimicrobial Agents and Chemotherapy*, **2016**, 60, 2336-42	5.9	25
92	Impact of Mucositis on Absorption and Systemic Drug Exposure of Isavuconazole. *Antimicrobial Agents and Chemotherapy*, **2017**, 61,	5.9	24
91	Pharmacodynamics of Tebipenem: New Options for Oral Treatment of Multidrug-Resistant Gram-Negative Infections. *Antimicrobial Agents and Chemotherapy*, **2019**, 63,	5.9	24
90	Combination of voriconazole and anidulafungin for treatment of triazole-resistant aspergillus fumigatus in an in vitro model of invasive pulmonary aspergillosis. *Antimicrobial Agents and Chemotherapy*, **2012**, 56, 5180-5	5.9	24
89	The pharmacology and clinical use of caspofungin. *Expert Opinion on Drug Metabolism and Toxicology*, **2007**, 3, 263-74	5.5	24
88	Pharmacodynamics of isavuconazole in experimental invasive pulmonary aspergillosis: implications for clinical breakpoints. *Journal of Antimicrobial Chemotherapy*, **2016**, 71, 1885-91	5.1	24
87	Delivering precision antimicrobial therapy through closed-loop control systems. *Journal of Antimicrobial Chemotherapy*, **2018**, 73, 835-843	5.1	23
86	Comparison of piperacillin exposure in the lungs of critically ill patients and healthy volunteers. *Journal of Antimicrobial Chemotherapy*, **2018**, 73, 1340-1347	5.1	22
85	Population pharmacokinetics of conventional and intermittent dosing of liposomal amphotericin B in adults: a first critical step for rational design of innovative regimens. *Antimicrobial Agents and Chemotherapy*, **2012**, 56, 5303-8	5.9	22
84	Fluconazole Monotherapy Is a Suboptimal Option for Initial Treatment of Cryptococcal Meningitis Because of Emergence of Resistance. *MBio*, **2019**, 10,	7.8	22
83	Twenty-four hour pharmacokinetic relationships for intravenous vancomycin and novel urinary biomarkers of acute kidney injury in a rat model. *Journal of Antimicrobial Chemotherapy*, **2019**, 74, 2326-2334	5.1	21
82	Population pharmacokinetics of teicoplanin in children. *Antimicrobial Agents and Chemotherapy*, **2014**, 58, 6920-7	5.9	21
81	AMBITION-cm: intermittent high dose AmBisome on a high dose fluconazole backbone for cryptococcal meningitis induction therapy in sub-Saharan Africa: study protocol for a randomized controlled trial. *Trials*, **2015**, 16, 276	2.8	21
80	Isolation of Aspergillus species from the airway of lung transplant recipients is associated with excess mortality. *Journal of Infection*, **2012**, 65, 350-6	18.9	21
79	Pharmacodynamics of amphotericin B deoxycholate, amphotericin B lipid complex, and liposomal amphotericin B against Aspergillus fumigatus. *Antimicrobial Agents and Chemotherapy*, **2015**, 59, 2735-45	5.9	20
78	Pharmacodynamics of Isavuconazole in a Dynamic In Vitro Model of Invasive Pulmonary Aspergillosis. *Antimicrobial Agents and Chemotherapy*, **2016**, 60, 278-87	5.9	20
77	Optimization of the dosage of flucytosine in combination with amphotericin B for disseminated candidiasis: a pharmacodynamic rationale for reduced dosing. *Antimicrobial Agents and Chemotherapy*, **2007**, 51, 3760-2	5.9	20
76	Gene expression profiles of human dendritic cells interacting with Aspergillus fumigatus in a bilayer model of the alveolar epithelium/endothelium interface. *PLoS ONE*, **2014**, 9, e98279	3.7	20

75	Invasive fungal infections. *Clinical Medicine*, **2013**, 13, 507-10	1.9	19
74	Comparison of the accuracy and precision of pharmacokinetic equations to predict free meropenem concentrations in critically ill patients. *Antimicrobial Agents and Chemotherapy*, **2015**, 59, 1411-7	5.9	19
73	Efficacy of an abbreviated induction regimen of amphotericin B deoxycholate for cryptococcal meningoencephalitis: 3 days of therapy is equivalent to 14 days. *MBio*, **2014**, 5, e00725-13	7.8	19
72	Experimental Models of Short Courses of Liposomal Amphotericin B for Induction Therapy for Cryptococcal Meningitis. *Antimicrobial Agents and Chemotherapy*, **2017**, 61,	5.9	18
71	A Phase 3 Study of Micafungin Versus Amphotericin B Deoxycholate in Infants With Invasive Candidiasis. *Pediatric Infectious Disease Journal*, **2018**, 37, 992-998	3.4	18
70	Population pharmacokinetics and dosing considerations for the use of daptomycin in adult patients with haematological malignancies. *Journal of Antimicrobial Chemotherapy*, **2017**, 72, 2342-2350	5.1	17
69	Intrapulmonary concentrations of meropenem administered by continuous infusion in critically ill patients with nosocomial pneumonia: a randomized pharmacokinetic trial. *Critical Care*, **2020**, 24, 55	10.8	15
68	Co-administration of proton pump inhibitors and/or of steroids may be a risk factor for low trough concentrations of posaconazole delayed-released tablets in adult patients with haematological malignancies. *British Journal of Clinical Pharmacology*, **2018**, 84, 2544-2550	3.8	15
67	The management of Candida infections in preterm neonates and the role of micafungin. *Journal of Maternal-Fetal and Neonatal Medicine*, **2011**, 24 Suppl 2, 24-7	2	15
66	Outcomes by MIC Values for Patients Treated with Isavuconazole or Voriconazole for Invasive Aspergillosis in the Phase 3 SECURE and VITAL Trials. *Antimicrobial Agents and Chemotherapy*, **2019**, 63,	5.9	15
65	Population Pharmacokinetics and Pharmacodynamics of Levofloxacin in Acutely Hospitalized Older Patients with Various Degrees of Renal Function. *Antimicrobial Agents and Chemotherapy*, **2017**, 61,	5.9	14
64	Pharmacokinetics and pharmacodynamics of anidulafungin for experimental Candida endophthalmitis: insights into the utility of echinocandins for treatment of a potentially sight-threatening infection. *Antimicrobial Agents and Chemotherapy*, **2013**, 57, 281-8	5.9	14
63	Isavuconazonium sulfate: a new agent for the treatment of invasive aspergillosis and invasive mucormycosis. *Expert Review of Clinical Pharmacology*, **2016**, 9, 887-97	3.8	14
62	Pharmacodynamics for antifungal drug development: an approach for acceleration, risk minimization and demonstration of causality. *Journal of Antimicrobial Chemotherapy*, **2016**, 71, 3008-3019	5.1	14
61	Optimising antimicrobial use in humans - review of current evidence and an interdisciplinary consensus on key priorities for research. *Lancet Regional Health - Europe, The*, **2021**, 7, 100161		14
60	Population pharmacokinetics and pharmacodynamics of fosfomycin in non-critically ill patients with bacteremic urinary infection caused by multidrug-resistant Escherichia coli. *Clinical Microbiology and Infection*, **2018**, 24, 1177-1183	9.5	13
59	Population pharmacokinetics and pharmacodynamics of teicoplanin in neonates: making better use of C-reactive protein to deliver individualized therapy. *Journal of Antimicrobial Chemotherapy*, **2016**, 71, 3168-3178	5.1	13
58	EUCAST technical note on posaconazole. *Clinical Microbiology and Infection*, **2011**, 17, E16-7	9.5	13

57	Single-Dose Liposomal Amphotericin B Treatment for Cryptococcal Meningitis.. *New England Journal of Medicine*, **2022**, 386, 1109-1120	59.2	13
56	A randomized open label trial of tamoxifen combined with amphotericin B and fluconazole for cryptococcal meningitis. *Wellcome Open Research*, **2019**, 4, 8	4.8	12
55	First dose in neonates: are juvenile mice, adults and in vitro-in silico data predictive of neonatal pharmacokinetics of fluconazole. *Clinical Pharmacokinetics*, **2014**, 53, 1005-18	6.2	12
54	A PCR method for the identification of methicillin-resistant Staphylococcus aureus (MRSA) from screening swabs. *Pathology*, **2004**, 36, 265-8	1.6	12
53	CSF penetration of vancomycin in critical care patients with proven or suspected ventriculitis: a prospective observational study. *Journal of Antimicrobial Chemotherapy*, **2019**, 74, 991-996	5.1	11
52	Pharmacodynamics of itraconazole against Aspergillus fumigatus in an in vitro model of the human alveolus: perspectives on the treatment of triazole-resistant infection and utility of airway administration. *Antimicrobial Agents and Chemotherapy*, **2012**, 56, 4146-53	5.9	11
51	Clinical pharmacology of antifungal agents in pediatrics: children are not small adults. *Current Opinion in Pharmacology*, **2015**, 24, 128-34	5.1	10
50	Voriconazole pharmacokinetics following HSCT: results from the BMT CTN 0101 trial. *Journal of Antimicrobial Chemotherapy*, **2016**, 71, 2234-40	5.1	10
49	Suboptimal Exposure to Anti-TB Drugs in a TBM/HIV+ Population Is Not Related to Antiretroviral Therapy. *Clinical Pharmacology and Therapeutics*, **2018**, 103, 449-457	6.1	9
48	Setting Our Sights on Infectious Diseases. *ACS Infectious Diseases*, **2020**, 6, 3-13	5.5	9
47	The Potential Role of Fosfomycin in Neonatal Sepsis Caused by Multidrug-Resistant Bacteria. *Drugs*, **2017**, 77, 941-950	12.1	8
46	Software for Dosage Individualization of Voriconazole: a Prospective Clinical Study. *Antimicrobial Agents and Chemotherapy*, **2019**, 63,	5.9	8
45	Pharmacodynamics of the Novel Metallo-β-Lactamase Inhibitor ANT2681 in Combination with Meropenem for the Treatment of Infections Caused by NDM-Producing. *Antimicrobial Agents and Chemotherapy*, **2020**, 64,	5.9	8
44	Pharmacodynamics of Cefepime Combined with the Novel Extended-Spectrum-β-Lactamase (ESBL) Inhibitor Enmetazobactam for Murine Pneumonia Caused by ESBL-Producing. *Antimicrobial Agents and Chemotherapy*, **2020**, 64,	5.9	8
43	Pharmacokinetics-pharmacodynamics of antifungal agents in the central nervous system. *Expert Opinion on Drug Metabolism and Toxicology*, **2018**, 14, 803-815	5.5	8
42	Population Pharmacokinetics of Anidulafungin in Critically Ill Patients. *Antimicrobial Agents and Chemotherapy*, **2019**, 63,	5.9	7
41	Population Pharmacokinetic Modeling of VL-2397, a Novel Systemic Antifungal Agent: Analysis of a Single- and Multiple-Ascending-Dose Study in Healthy Subjects. *Antimicrobial Agents and Chemotherapy*, **2019**, 63,	5.9	7
40	Linezolid underexposure in a patient co-treated with venlafaxine. *European Journal of Clinical Pharmacology*, **2015**, 71, 1285-6	2.8	7

39	Tools for the Individualized Therapy of Teicoplanin for Neonates and Children. *Antimicrobial Agents and Chemotherapy*, **2017**, 61,	5.9	7
38	Urine D-arabinitol/L-arabinitol ratio in diagnosing Candida infection in patients with haematological malignancy and HIV infection. *Diagnostic Microbiology and Infectious Disease*, **2002**, 42, 39-42	2.9	7
37	Population Pharmacokinetics and Cerebrospinal Fluid Penetration of Fluconazole in Adults with Cryptococcal Meningitis. *Antimicrobial Agents and Chemotherapy*, **2018**, 62,	5.9	7
36	Pharmacodynamics of Isavuconazole in a Rabbit Model of Cryptococcal Meningoencephalitis. *Antimicrobial Agents and Chemotherapy*, **2019**, 63,	5.9	6
35	Exploring the Use of C-Reactive Protein to Estimate the Pharmacodynamics of Vancomycin. *Therapeutic Drug Monitoring*, **2018**, 40, 315-321	3.2	6
34	Application of the hollow fibre infection model (HFIM) in antimicrobial development: a systematic review and recommendations of reporting. *Journal of Antimicrobial Chemotherapy*, **2021**, 76, 2252-2259	5.1	6
33	Population pharmacokinetics of continuous-infusion ceftazidime in febrile neutropenic children undergoing HSCT: implications for target attainment for empirical treatment against Pseudomonas aeruginosa. *Journal of Antimicrobial Chemotherapy*, **2019**, 74, 1648-1655	5.1	5
32	Pharmacodynamics of Voriconazole for Invasive Pulmonary Scedosporiosis. *Antimicrobial Agents and Chemotherapy*, **2018**, 62,	5.9	5
31	Population Pharmacokinetic Model and Meta-analysis of Outcomes of Amphotericin B Deoxycholate Use in Adults with Cryptococcal Meningitis. *Antimicrobial Agents and Chemotherapy*, **2018**, 62,	5.9	5
30	Can We Achieve Clinical Breakpoints for the Triazoles in Aspergillosis?. *Current Fungal Infection Reports*, **2011**, 5, 128-134	1.4	5
29	Optimising antifungal therapy for individual patients. *Internal Medicine Journal*, **2004**, 34, 147-9	1.6	5
28	Invasive pulmonary aspergillosis with spontaneous resolution and the diagnostic utility of PCR from tissue specimens. *Journal of Infection*, **2004**, 49, 136-40	18.9	5
27	Intrapulmonary Pharmacokinetics of Cefepime and Enmetazobactam in Healthy Volunteers: Towards New Treatments for Nosocomial Pneumonia. *Antimicrobial Agents and Chemotherapy*, **2020**, 65,	5.9	5
26	Amikacin Combined with Fosfomycin for Treatment of Neonatal Sepsis in the Setting of Highly Prevalent Antimicrobial Resistance. *Antimicrobial Agents and Chemotherapy*, **2021**, 65, e0029321	5.9	5
25	Cryptococcal meningoencephalitis: time for action. *Lancet Infectious Diseases, The*, **2021**, 21, e259-e271	25.5	5
24	Population pharmacokinetics of fluconazole in liver transplantation: implications for target attainment for infections with Candida albicans and non-albicans spp. *European Journal of Clinical Pharmacology*, **2018**, 74, 1449-1459	2.8	4
23	Optimizing micafungin dosing in children. *Pediatric Infectious Disease Journal*, **2012**, 31, 1211-2; author reply 1212	3.4	4
22	FDA Public Workshop Summary: Advancing Animal Models for Antibacterial Drug Development. *Antimicrobial Agents and Chemotherapy*, **2020**, 65,	5.9	4

21	Higher than standard meropenem and linezolid dosages needed for appropriate treatment of an intracerebral hemorrhage patient with augmented renal clearance. *European Journal of Clinical Pharmacology*, **2018**, 74, 1091-1092	2.8	3
20	Combination therapy for carbapenemase-producing Entero-bacteriaceae: INCREMENT-al effect on resistance remains unclear. *Lancet Infectious Diseases, The*, **2017**, 17, 899-900	25.5	3
19	Aspergillus **2009**, 271-296		3
18	Sequential infection with Nocardia farcinica and Cryptococcus neoformans var. gattii in an immunocompetent host. *Journal of Infection*, **2003**, 47, 256-9	18.9	3
17	Population Pharmacodynamics of Amphotericin B Deoxycholate for Disseminated Infection Caused by. *Antimicrobial Agents and Chemotherapy*, **2019**, 63,	5.9	3
16	Pharmacodynamics of Posaconazole in Experimental Invasive Pulmonary Aspergillosis: Utility of Serum Galactomannan as a Dynamic Endpoint of Antifungal Efficacy. *Antimicrobial Agents and Chemotherapy*, **2021**, 65,	5.9	3
15	Potential Antibiotics for the Treatment of Neonatal Sepsis Caused by Multidrug-Resistant Bacteria. *Paediatric Drugs*, **2021**, 23, 465-484	4.2	3
14	Population Pharmacokinetics of Praziquantel in Pregnant and Lactating Filipino Women Infected with Schistosoma japonicum. *Antimicrobial Agents and Chemotherapy*, **2020**, 64,	5.9	2
13	Clinical utility of micafungin: pharmacokinetics, dosing, use in special populations and drug interactions. *Mycoses*, **2012**, 55, 33-38	5.2	2
12	Clinical research in the lay press: irresponsible journalism raises a huge dose of doubt. *Clinical Infectious Diseases*, **2006**, 43, 1031-9	11.6	2
11	Exposure-Response Analysis of Micafungin in Neonatal Candidiasis: Pooled Analysis of Two Clinical Trials. *Pediatric Infectious Disease Journal*, **2018**, 37, 580-585	3.4	2
10	Vancomycin therapy in secondary care; investigating factors that impact therapeutic target attainment. *Journal of Infection*, **2017**, 74, 320-324	18.9	1
9	1210A Phase 3, Randomized, Double-Blind, Non-inferiority Trial to Evaluate Efficacy and Safety of Isavuconazole versus Voriconazole in Patients with Invasive Mold Disease (SECURE): Outcomes in Neutropenic Patients. *Open Forum Infectious Diseases*, **2014**, 1, S36-S37	1	1
8	Flomoxef for neonates: extending options for treatment of neonatal sepsis caused by ESBL-producing Enterobacterales.. *Journal of Antimicrobial Chemotherapy*, **2021**,	5.1	1
7	Efficacy and Associated Drug Exposures of Isavuconazole and Fluconazole in an Experimental Model of Coccidioidomycosis. *Antimicrobial Agents and Chemotherapy*, **2021**, 65,	5.9	1
6	Population Pharmacokinetics and Pharmacodynamics of Itraconazole for Disseminated Infection Caused by Talaromyces marneffei. *Antimicrobial Agents and Chemotherapy*, **2021**, 65, e0063621	5.9	1
5	An open label randomized controlled trial of tamoxifen combined with amphotericin B and fluconazole for cryptococcal meningitis. *ELife*, **2021**, 10,	8.9	1
4	Standard ganciclovir dosing results in slow decline of cytomegalovirus viral loads.. *Journal of Antimicrobial Chemotherapy*, **2022**, 77, 466-473	5.1	0

3	Antifungal Pharmacokinetics and Pharmacodynamics. *Methods in Pharmacology and Toxicology*, **2016**, 369-383	1.1
2	Antifungal Dosing Considerations for Term and Preterm Infants **2019**, 185-191	
1	Pharmacodynamics of Meropenem and Tobramycin for Neonatal Meningoencephalitis: Novel Approaches to Facilitate the Development of New Agents to Address the Challenge of Antimicrobial Resistance.. *Antimicrobial Agents and Chemotherapy*, **2022**, e0218121	5.9